FDA approves Amgen’s T cell engager in aggressive form of lung cancer
The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up
The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up
British drugmaker GSK will sell off the rest of its share in Haleon after slowly selling off multibillion-dollar pieces of its ownership in the consumer
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) More pharma companies are considering taking a
A new obesity biotech has entered the field — and it has $400 million from well-known life sciences investors to test investigational GLP-1 and GIP
Roche is back to square one for finding a partner to carry forward its culled Angelman syndrome drug. Last June, the Swiss pharma had started
WASHINGTON — Lawmakers advanced the reauthorization of an FDA program designed to stimulate the development of treatments for pediatric rare diseases, despite some opposition from
Just two months after earning another approval for its blockbuster blood cancer drug Breyanzi, Bristol Myers Squibb can add an accelerated approval to the list,
NEW YORK — Facing a challenging launch for the Alzheimer’s drug Leqembi, Biogen CEO Chris Viehbacher said he would welcome competition from other companies, including
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. WuXi Biologics has “temporarily paused” the
Pfizer and Arvinas’ targeted protein degrader plus Ibrance has shown promising efficacy in breast cancer patients in updated data from an early-stage trial, raising anticipation